| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
β-lactam
Ceftizoxime targets penicillin-binding proteins (PBPs) in the bacterial cell wall. By binding to PBPs, it inhibits the final transpeptidation step required for cross-linking of peptidoglycan units, which are a component of the cell wall. This leads to inhibition of bacterial cell wall synthesis and cell death. |
|---|---|
| ln Vitro |
Ceftizoxime is a parenterally administered third-generation cephalosporin. Ceftizoxime, in contrast to other third-generation cephalosporins, has had its entire C-3 side chain removed to prevent hydrolytic enzyme deactivation. Its characteristics are rather similar to those of cefotaxime, but it is not metabolized.
In vitro, Ceftizoxime demonstrates broad-spectrum antibacterial activity against a wide variety of Gram-positive and Gram-negative bacteria, both aerobic and anaerobic. It is commonly used in clinical in vitro microbiological antimicrobial susceptibility tests (panels, discs, and MIC strips) against Gram-positive and Gram-negative organisms. |
| ln Vivo |
In vivo, Ceftizoxime is effective in treating various bacterial infections. As a third-generation cephalosporin, it has enhanced activity against Gram-negative bacteria compared to earlier generations. It is administered parenterally for the treatment of serious infections.
|
| Enzyme Assay |
In vitro susceptibility testing for cephalosporins typically uses broth microdilution or agar dilution methods according to CLSI guidelines. Bacterial cultures are prepared at a standardized inoculum and incubated with varying concentrations of Ceftizoxime. Minimum inhibitory concentrations (MICs) are determined as the lowest concentration that inhibits visible bacterial growth after 18-24 hours of incubation.
|
| Cell Assay |
In vitro cellular assays for antibiotics typically involve bacterial cell culture. Bacteria are grown in appropriate media and treated with varying concentrations of Ceftizoxime. Bacterial growth is monitored by measuring optical density (OD600) over time to generate growth curves. Time-kill assays are performed to determine bactericidal activity.
|
| Animal Protocol |
In vivo animal studies for antibacterial efficacy typically use mouse or rat models of infection. Animals are infected with a pathogenic bacterial strain and treated with Ceftizoxime at various doses via parenteral administration. Bacterial load in target organs (e.g., lungs, blood) is determined by CFU counting. Survival is monitored as an endpoint.
|
| ADME/Pharmacokinetics |
Ceftizoxime Sodium is administered parenterally (intravenously or intramuscularly) for the treatment of bacterial infections. It distributes well to various tissues and body fluids. The compound is eliminated primarily via the kidneys, and dose adjustment is required in patients with renal impairment.
|
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Limited information currently available indicates that cefotaxime concentrations in breast milk are low and are not expected to have adverse effects on breastfed infants. There are reports that cephalosporins occasionally disrupt the infant's gut microbiota, leading to diarrhea or thrush, but these effects have not been fully assessed. Cefotaxime is safe for use by breastfeeding women. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Ceftizoxime is generally well-tolerated at therapeutic doses. Common side effects may include gastrointestinal disturbances, rash, and injection site reactions. Hypersensitivity reactions, including anaphylaxis, may occur in penicillin-allergic patients. As with other cephalosporins, caution should be exercised in patients with a history of penicillin allergy. |
| References |
Türkeş C, Söyüt H, Beydemir Ş. Human serum paraoxonase-1 (hPON1): in vitro
inhibition effects of moxifloxacin hydrochloride, levofloxacin hemihidrate,
cefepime hydrochloride, cefotaxime sodium and ceftizoxime sodium. J Enzyme Inhib
Med Chem. 2015;30(4):622-8. doi: 10.3109/14756366.2014.959511. Epub 2014 Dec 18.
PubMed PMID: 25519764.
|
| Additional Infomation |
Cefotaxime sodium is the sodium salt of cefotaxime. It contains one cefotaxime (1-) molecule. Cefotaxime sodium, the sodium salt form of cefotaxime, is a semi-synthetic, broad-spectrum, β-lactamase-resistant third-generation cephalosporin antibiotic with bactericidal activity. Cefotaxime sodium inhibits bacterial cell wall synthesis by inactivating penicillin-binding proteins (PBPs), thereby interfering with the final transpeptidation step required for peptidoglycan unit cross-linking, which is a component of the cell wall. Lack of cross-linking leads to decreased cell wall stability, ultimately resulting in cell lysis. This is a semi-synthetic cephalosporin antibiotic, administered intravenously or via suppository. The drug exhibits high resistance to multiple β-lactamases and is effective against a wide range of aerobic and anaerobic Gram-positive and Gram-negative bacteria. It has few side effects and has been reported to be safe and effective in elderly patients and patients with hematologic disorders.
Ceftizoxime Sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by targeting penicillin-binding proteins. It is effective against a broad range of Gram-positive and Gram-negative bacteria and is administered parenterally. The compound is used for the treatment of various bacterial infections and is available for research and clinical use. |
| Molecular Formula |
C13H12N5NAO5S2
|
|---|---|
| Molecular Weight |
405.38
|
| Exact Mass |
405.017
|
| Elemental Analysis |
C, 38.52; H, 2.98; N, 17.28; Na, 5.67; O, 19.73; S, 15.82
|
| CAS # |
68401-82-1
|
| Related CAS # |
Ceftizoxime;68401-81-0
|
| PubChem CID |
23663938
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
26
|
| Complexity |
675
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
O=C(C(N12)=CCS[C@]2([H])[C@H](NC(/C(C3=CSC(N)=N3)=N\OC)=O)C1=O)[O-].[Na+]
|
| InChi Key |
ADLFUPFRVXCDMO-LIGXYSTNSA-M
|
| InChi Code |
InChI=1S/C13H13N5O5S2.Na/c1-23-17-7(5-4-25-13(14)15-5)9(19)16-8-10(20)18-6(12(21)22)2-3-24-11(8)18;/h2,4,8,11H,3H2,1H3,(H2,14,15)(H,16,19)(H,21,22);/q;+1/p-1/b17-7-;/t8-,11-;/m1./s1
|
| Chemical Name |
sodium;(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
|
| Synonyms |
Ceftizoxime Sodium; Ceftizoxim-natrium; Cefizox; Epocelin; Eposerin; Ceftizoxime sodium salt; Monosodium Salt, Ceftizoxime; Salt, Ceftizoxime Monosodium; SK and F 88373 2; SK and F 88373-2; SK and F 883732; SKF 88373; SKF-88373; SKF88373;
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product is not stable in solution, please use freshly prepared working solution for optimal results. (2). Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 81~100 mg/mL (199.81~246.68 mM )
DMSO : ~15 mg/mL (~37.00 mM) Water : ~81 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4668 mL | 12.3341 mL | 24.6682 mL | |
| 5 mM | 0.4934 mL | 2.4668 mL | 4.9336 mL | |
| 10 mM | 0.2467 mL | 1.2334 mL | 2.4668 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
